ArticleCNS oncology2014
Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival.
Article in CNS oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 45 citations in OpenAlex.
- Clinical predictors of pseudoprogression in glioblastoma: a retrospective cohort analysis.Journal of neuro-oncology · 2025Article
- Comparative Outcomes of Standard Radiation Therapy and 5-Fraction Adaptive Stereotactic Radiation Therapy in Newly Diagnosed Glioblastoma: A Propensity Score-Matched Analysis.Advances in radiation oncology · 2025Article
- Detecting pseudo versus true progression of glioblastoma via accurate quantitative DCE-MRI using point-of-care portable perfusion phantoms: a pilot study.Quantitative imaging in medicine and surgery · 2025Article
- Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know.Journal of neurosurgery · 2023Review
- Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses.Journal of neuro-oncology · 2023Article
- [Neuro-oncology practice · 2022Article
- MRI and PET of Brain Tumor Neuroinflammation in the Era of Immunotherapy, From theAJR. American journal of roentgenology · 2022Review
- Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions.Frontiers in radiology · 2022Review
- Freiburg Neuropathology Case Conference : Contrast-enhancing Brain Lesion 6 Months after Resection and Combined Radiotherapy and Chemotherapy of an Unmethylated but IDH R132H-mutated Glioblastoma Multiforme.Clinical neuroradiology · 2021Article
- Dual MGMT inactivation by promoter hypermethylation and loss of the long arm of chromosome 10 in glioblastoma.Cancer medicine · 2020Article
- Isocitrate dehydrogenase 1 mutant glioblastomas demonstrate a decreased rate of pseudoprogression: a multi-institutional experience.Neuro-oncology practice · 2020Article
- Restriction Spectrum Imaging Differentiates True Tumor Progression From Immune-Mediated Pseudoprogression: Case Report of a Patient With Glioblastoma.Frontiers in oncology · 2020Article
- Synthesis, Characterization, andFrontiers in pharmacology · 2020Article
- Review
- Increased risk of pseudoprogression among pediatric low-grade glioma patients treated with proton versus photon radiotherapy.Neuro-oncology · 2019Article
- Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.Journal of neuro-oncology · 2019Article
- Institutional review of glial tumors treated with chemotherapy: the first description of PCV-related pseudoprogression.Neuro-oncology practice · 2019Article
- Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.Journal of neuro-oncology · 2018Article
- Neurovascular Unit: Basic and Clinical Imaging with Emphasis on Advantages of Ferumoxytol.Neurosurgery · 2018Review
- Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma.Clinical and translational radiation oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
aimsThis retrospective study determined the survival of glioblastoma patients with or without pseudoprogression.
methodsA total of 68 patients were included. Overall survival was compared between patients showing pseudoprogression (in most cases diagnosed using perfusion MRI with ferumoxytol) and in patients without pseudoprogession. MGMT methylation status was also analyzed in the pseudoprogression cases.
resultsMedian survival in 24 (35.3%) patients with pseudoprogression was 34.7 months (95% CI: 20.3-54.1), and 13.4 months (95% CI: 11.1-19.5) in 44 (64.7%) patients without pseudoprogression (p < 0.0001). The longest survival was a median of 54.1 months in patients with combination of pseudoprogression and (MGMT) promoter methylation.
conclusionPseudoprogression is associated with better outcome, especially if concurring with MGMT promoter methylation. Patients never diagnosed with pseudoprogression had poor survival. This study emphasizes the importance of differentiating tumor progression and pseudoprogression using perfusion MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.